No Data
Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference
Esperion Therapeutics Analyst Ratings
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
Esperion Highlights New Exploratory Data From CLEAR Outcomes Trial Highlighting Value Of NEXLETOL In Oral Featured Science Session And Multiple Poster Presentations At AHA Scientific Sessions 2024; Exploratory Analysis Reports Patients With PAD Who...
US Manufacturing Index Rises To 43, Highest Since 2020
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)